Dynegy Aktie
WKN DE: A1J5JU / ISIN: US26817R1086
04.08.2025 14:00:01
|
Dyne Therapeutics Announces Breakthrough Therapy Designation For DYNE-251
(RTTNews) - Dyne Therapeutics (DYN) announced the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with Duchenne muscular dystrophy, amenable to exon 51 skipping. The designation is based on data from the DELIVER clinical trial.
Dyne anticipates a potential BLA submission for U.S. Accelerated Approval in early 2026. Dyne continues to pursue approval pathways outside of the U.S. for DYNE-251 in patients with DMD with a confirmed mutation amenable to exon 51 skipping.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Dynegy Incmehr Nachrichten
Keine Nachrichten verfügbar. |